Disease · MONDO_0019514

hepatic veno-occlusive disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hepatic veno-occlusive disease. Diseases, record MONDO_0019514. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019514

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hepatic veno-occlusive disease; Open Targets
Open Targets ID: MONDO_0019514; Open Targets
Other names: Budd Chiari Syndrome, hepatic Vod, liver veno-occlusive disease, sinusoidal obstruction syndrome; Open Targets
Disease Ontology: DOID:0080177; Disease Ontology
MeSH: D006504; MeSH
NCI Thesaurus: C26793; NCI Thesaurus
Orphanet: ORPHA:890; Orphanet
Highest stage of its drugs: Approval, for 2 of its 8 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEFIBROTIDE	CHEMBL2108396		Approval	EMA Human Drugs and TTD	8	5	5	Drugs and targets
DEFIBROTIDE SODIUM	CHEMBL3707226	Oligonucleotide	Approval	DailyMed, FDA and PMDA	4	0	0	Drugs and targets
ANTITHROMBIN III HUMAN	CHEMBL2108574		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BUSULFAN	CHEMBL820	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
HEPARIN	CHEMBL4650299	Oligosaccharide	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
OPRELVEKIN	CHEMBL1201573	Protein	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets
RECOMBINANT HUMAN THROMBOPOIETIN	CHEMBL4802180		Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PLG	Plasminogen	2	Plasminogen activator	Approval	https://conductscience.org/library/genes/5340	Drugs and targets
ADORA1	Adenosine receptor A1	1	Adenosine A1 receptor agonist	Approval	https://conductscience.org/library/genes/134	Drugs and targets
ADORA2A	Adenosine A2 receptor	1	Adenosine A2 receptor agonist	Approval	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	1	Adenosine A2 receptor agonist	Approval	https://conductscience.org/library/genes/136	Drugs and targets
F2	Prothrombin	1	Thrombin antagonist	Approval	https://conductscience.org/library/genes/2147	Drugs and targets
IL11RA	Interleukin-11 receptor subunit alpha	1	Interleukin 11 receptor alpha agonist	Unknown	https://conductscience.org/library/genes/3590	Drugs and targets
SERPINC1	Antithrombin-III	1	Antithrombin-III activator	Unknown	https://conductscience.org/library/genes/462	Drugs and targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00628498	Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study	Phase 3	1,206	2017-11-30	Hepatic Veno-Occlusive Disease	DEFIBROTIDE	Its record names the disease	ClinicalTrials.gov
NCT02281240	Hemostatic Complications in Hematopoietic Stem Cell Transplantation		200		Hemostatic Disorders	HEPARIN, RECOMBINANT HUMAN THROMBOPOIETIN	Its record names the disease	ClinicalTrials.gov
NCT00003966	Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation	Phase 2	151		Veno-occlusive Disease	DEFIBROTIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01779882	Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT	Not applicable	72		Myeloid Leukemia, Precursor Myeloid Neoplasms, Lymphoid Neoplasms	BUSULFAN, CYCLOPHOSPHAMIDE	Its record names the disease	ClinicalTrials.gov
NCT01886248	Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation	Phase 2	32		Hepatic Veno-Occlusive Disease	ANTITHROMBIN III HUMAN	Its record names the disease	ClinicalTrials.gov
NCT04313036	5-day Defibrotide Treatment for Hepatic SOS/VOD	Phase 2	24		Sinusoidal Obstruction Syndrome, Veno-occlusive Disease, Bone Marrow Transplant Complications	DEFIBROTIDE	Its record names the disease	ClinicalTrials.gov
NCT05987124	Defibrotide Dose-escalation for SOS Post-HSCT	Phase 2	20		Sinusoidal Obstruction Syndrome, Veno-occlusive Disease	DEFIBROTIDE	Its record names the disease	ClinicalTrials.gov
NCT00263978	Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver				Liver Diseases	DEFIBROTIDE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
12393437	RESULT	1	PubMed
37085674	DERIVED	1	PubMed
32950693	DERIVED	1	PubMed
29767845	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019514

GET https://conductscience.org/api/diseases/v1/MONDO_0019514/drugs

API reference For AI assistants